Basic Terbinafine Information

• INN (International Nonproprietary Name): Terbinafine
• Brand Names Available In United Kingdom: Lamisil, Terbinex
• ATC Code: D01BA02
• Forms & Dosages: Tablets 250 mg (oral); Cream 1% and Spray 1% (topical); Granules 125 mg and 187.5 mg (paediatric oral)
• Manufacturers In United Kingdom: Marketed internationally by companies including Novartis, Taro, Mylan and available in the UK market via national registrations and local packagers
• Registration Status In United Kingdom: Marketed via national registrations in the EU/UK (EMA national registrations noted)
• OTC / Rx Classification: Oral tablets are prescription-only (Rx); many small-pack topical 1% products are available OTC

Everyday Use & Best Practices

Morning Vs Evening Dosing

The usual NHS regimen for oral terbinafine is 250 mg once daily in tablet form.

Taking tablets at the same time each day helps adherence and makes treatment simpler to follow.

Many UK patients prefer taking terbinafine in the morning with breakfast to fit their daily routine.

Taking the tablet in the evening is equally acceptable if that improves consistency for the individual.

For topical 1% cream or spray, apply to the affected area once or twice daily as directed until the visible rash clears and for a few days afterwards.

Taking With Or Without Meals (UK Diet Habits)

Terbinafine tablets may be taken with or without food depending on personal tolerance.

Having the tablet with a light or hearty UK breakfast can reduce nausea for people who experience gastrointestinal upset.

For topical products, dry the skin thoroughly before applying cream or spray for best effect.

• Checklist For Daily Routine: Take 250 mg tablet at the same time each day; apply topical cream/spray to clean, dry skin 1–2 times daily; store medication at 15–30°C.

• Missed Dose Advice: Take as soon as remembered unless it is close to the next dose; do not double dose.

Safety Priorities

Who Should Avoid It (MHRA Warnings)

Do not use systemic terbinafine if there is a known hypersensitivity to terbinafine or to any excipients in the product.

Oral terbinafine is contraindicated in people with chronic or active liver disease.

Pregnancy and breastfeeding are relative cautions; systemic terbinafine is generally avoided in pregnancy and lactation while topical use may be considered with caution.

Baseline liver function tests and monitoring during oral therapy are standard practice for systemic use.

Activities To Limit (Driving, Work Safety)

Most people can drive and operate machinery normally while taking terbinafine.

Terbinafine can cause headache, dizziness or fatigue in some people; avoid heavy machinery or safety-critical tasks if these effects occur.

Avoid excessive alcohol while taking oral terbinafine because of the added strain on the liver.

If you suspect a serious adverse reaction, report it via the MHRA Yellow Card scheme.

Dosage & Adjustments

General Regimen (NHS Guidance)

The standard adult oral dosage for terbinafine is 250 mg once daily.

Indication-specific durations from published data include fingernail onychomycosis for 6 weeks and toenail onychomycosis for 12 weeks.

For tinea corporis and tinea cruris systemic courses are commonly 2–4 weeks, and systemic treatment for tinea pedis ranges 2–6 weeks depending on severity.

Topical 1% cream or spray is typically applied once or twice daily for 1–4 weeks depending on the product and severity of the infection.

Special Cases (Elderly, Comorbidities)

Children may receive weight-based oral dosing, with granules or paediatric tablets used for tinea capitis: 125 mg for under 20 kg, 187.5 mg for 20–40 kg and 250 mg for over 40 kg.

Elderly patients do not require routine dose adjustment but should have hepatic and renal function monitored.

Systemic terbinafine is contraindicated in chronic or active liver disease; severe renal impairment requires caution and dose review.

• Dosing Summary By Indication: Onychomycosis (fingernail) 250 mg once daily × 6 weeks; Onychomycosis (toenail) 250 mg once daily × 12 weeks; Tinea corporis/cruris 250 mg once daily × 2–4 weeks; Tinea pedis 250 mg once daily × 2–6 weeks; Topical mild tinea: cream/spray 1–2× daily × 1–4 weeks.

• Missed Dose: Take when remembered unless near next dose; do not double dose.

User Testimonials

Positive Reports From UK Patients

Many UK patients report faster resolution of athlete’s foot when using topical 1% terbinafine cream or spray.

Patients treating nail infections often praise the convenience of once-daily tablets such as Lamisil for adherence during lengthy courses.

Positive posts highlight nail improvement several weeks after completing a 6–12 week oral course, with visible regrowth over months.

Common Challenges (Patient.Info, NHS Forums)

Forum discussions commonly mention taste disturbance and prolonged cosmetic recovery of nails even after the fungus is eradicated.

Recurrence and lengthy treatment courses worry many patients, and some prefer topical options because of concerns about liver testing.

• What To Tell Your GP Or Pharmacist: Describe symptoms and duration, list all current medicines, report alcohol intake, mention pregnancy/breastfeeding status and any history of liver disease.

Buying Guide

Pharmacy Sources (Boots, LloydsPharmacy, Superdrug)

Topical terbinafine 1% cream and spray are widely available OTC from major UK chains such as Boots, LloydsPharmacy and Superdrug as well as NHS community pharmacies.

Oral terbinafine 250 mg tablets are prescription-only and must be obtained via a GP, urgent care clinic or private clinics and may be supplied under local pharmacy PGD/minor ailments schemes in some areas.

Price Comparison (NHS Prescription Charge Vs Private)

In England prescription charges apply per item, while Scotland, Wales and Northern Ireland have different prescription charging arrangements.

Private prescription prices and private clinic fees vary, and branded products such as Lamisil can cost more than generic terbinafine tablets.

Buying from unregulated international or non-UK online sellers risks counterfeit products and should be avoided.

In our online pharmacy, terbinafine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

What’s Inside & How It Works

Ingredients Overview

The active ingredient is terbinafine (INN), an allylamine with ATC code D01BA02.

Typical formulations include 250 mg oral tablets, 1% topical cream or spray, and paediatric granules of 125 mg and 187.5 mg.

Branded names available internationally include Lamisil and Terbinex, with manufacturers such as Novartis, Taro and Mylan noted.

Mechanism Basics Explained Simply

Terbinafine inhibits the fungal enzyme squalene epoxidase, which is essential for producing ergosterol for fungal cell membranes.

Interruption of ergosterol synthesis causes accumulation of squalene and leads to fungal cell death.

• Formulation → Typical Uses → Action:
• Topical 1% cream/spray → Athlete’s foot, ringworm, jock itch → Local inhibition of squalene epoxidase.
• Oral 250 mg tablets → Onychomycosis and deeper infections → Systemic delivery to nail bed and skin.

Main Indications

Approved Uses (MHRA Listing)

Terbinafine is approved for onychomycosis (fungal nail infection), tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea capitis, particularly in paediatrics.

Topical forms are first-line for mild cutaneous tinea, while systemic tablets are standard for onychomycosis.

Off-Label Uses In UK Clinics

Occasionally clinicians may use terbinafine off-label for certain cutaneous candidiasis or mixed infections when judged appropriate.

The choice between topical and systemic therapy depends on severity, site of infection and patient factors such as pregnancy or liver disease.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

There are no major interactions with common beverages such as tea or coffee.

Limit alcohol intake during oral terbinafine therapy because of potential liver effects and the need for liver monitoring.

Drug Conflicts (MHRA Yellow Card Reports)

Terbinafine is a CYP2D6 inhibitor and can interact with medicines metabolised by this enzyme.

Common interacting drug classes include certain antidepressants, beta-blockers and some antipsychotics; dose adjustments or alternative therapies may be needed.

• Common Interacting Classes: Antidepressants, Beta-Blockers, Some Antipsychotics.
• Advice: Always check interactions with your pharmacist or GP and report suspected problems via the MHRA Yellow Card scheme.

Latest Evidence & Insights

Recent UK and EU evidence up to 2025 continues to support systemic terbinafine as the gold standard for onychomycosis because of superior mycological and clinical cure rates compared with many azoles.

Topical terbinafine remains effective for uncomplicated tinea corporis, cruris and pedis and is often preferred for limited disease.

Surveillance reports indicate resistance in dermatophytes is uncommon but does occur and should be suspected with persistent or recurrent infections.

Safety data support baseline and on-treatment liver monitoring for oral courses, and clinicians continue to avoid systemic terbinafine in active liver disease.

Alternative Choices

NHS alternatives to terbinafine include systemic itraconazole or fluconazole for certain infections and topical azoles such as clotrimazole or ketoconazole for cutaneous tinea.

Ciclopirox lacquer is a topical option for nails with modest efficacy and fewer systemic risks.

• Itraconazole: Effective for nails; higher drug interaction potential and hepatotoxicity risk; pulse dosing options available.
• Fluconazole: Alternative systemic agent with variable nail cure rates depending on organism.
• Topical Azoles (Clotrimazole): Good for superficial tinea with minimal systemic risk.
• Ciclopirox: Topical lacquer for nails with modest efficacy and low systemic exposure.

Choice depends on the organism, site of infection, pregnancy status, liver function and cost considerations.

For pregnant or breastfeeding women topical azoles are often preferred and systemic agents are usually avoided unless essential.

Regulation Snapshot

Terbinafine is marketed in the UK under brands such as Lamisil and is classified with ATC code D01BA02.

Oral tablets are prescription-only while many small-pack topical 1% products are available OTC in the UK.

The MHRA oversees licensing and adverse-event reporting in the UK and clinicians should follow MHRA and NHS formulary guidance for prescribing and monitoring.

• Regulatory Checklist: Oral = Prescription-only; Topical = OTC in many small packs; Report adverse reactions via MHRA Yellow Card; Follow NHS formulary references and local pharmacy PGDs where applicable.

FAQ Section

Q1: Can I Get Terbinafine On The NHS?

A1: Topical forms are widely available OTC; oral 250 mg tablets require a GP prescription.

Q2: How Will My Liver Be Checked?

A2: Baseline liver function tests are commonly done before starting oral terbinafine and repeated if symptoms or prolonged therapy occur.

Q3: How Long Until My Nail Looks Better?

A3: Nails can take months to look better; treatment clears fungus in weeks but cosmetic regrowth for nails follows over months.

Q4: Can I Drink Alcohol?

A4: Limit alcohol during oral treatment because of liver monitoring needs.

For more detailed official advice consult NHS or MHRA guidance and speak to your GP or pharmacist.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Confirm allergy history and current medicines, emphasising drugs metabolised by CYP2D6.

Ask about pregnancy or breastfeeding, alcohol use and any history of liver disease before recommending systemic terbinafine.

Explain the oral dose (250 mg daily), duration by indication, need for baseline LFTs and common side effects such as taste change, GI upset and headache.

Advise on missed-dose instructions and encourage reporting of adverse events via the Yellow Card scheme.

NHS Patient Support Advice

Advise patients to keep feet dry, change socks daily and avoid sharing towels and footwear to reduce reinfection risk.

Treat household contacts where appropriate for recurrent infections and clean footwear and socks during treatment.

Store medicines between 15–30°C in a dry place and protect topical forms from moisture.

• Counselling Checklist: Confirm allergies, list of medicines, alcohol intake, explain dosing and duration, discuss LFT testing, outline prevention steps and follow-up plan.

Delivery Across United Kingdom